BACKGROUND: Gene therapy with inducible nitric oxide synthase (iNOS) markedly reduces myocardial infarct size; this effect is associated with cyclooxygenase-2 (COX-2) upregulation and is ablated by COX-2 inhibitors. However, pharmacological inhibitors are limited by relative lack of specificity; furthermore, the mechanism whereby iNOS gene therapy upregulates COX-2 remains unknown. Accordingly, we used genetically engineered mice to test the hypothesis that the cardioprotection afforded by iNOS gene transfer is mediated by COX-2 upregulation via a nuclear factor (NF)-kappaB-dependent pathway. METHODS AND RESULTS: Mice received an intramyocardial injection of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 3 days later, myocardial infarction was produced by a 30-minute coronary occlusion followed by 4 hours of reperfusion. Among Av3/LacZ-treated mice, infarct size was similar in COX-2(-/-) and wild-type groups. iNOS gene transfer (confirmed by iNOS immunoblotting and activity assays) markedly reduced infarct size in wild-type mice but failed to do so in COX-2(-/-) mice. In transgenic mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha(S32A,S36A)), the upregulation of phosphorylated IkappaB alpha, activation of NF-kappaB, and cardiac COX-2 protein expression 3 days after iNOS gene therapy were abrogated, which was associated with the abolishment of the cardioprotective effects afforded by iNOS gene therapy. CONCLUSIONS: These data provide strong genetic evidence that COX-2 is an obligatory downstream effector of iNOS-dependent cardioprotection and that NF-kappaB is a critical link between iNOS and COX-2. Thus, iNOS imparts its protective effects, at least in part, by recruiting NF-kappaB, leading to COX-2 upregulation. However, COX-2 does not play an important cardioprotective role under basal conditions (when iNOS is not upregulated).
BACKGROUND: Gene therapy with inducible nitric oxide synthase (iNOS) markedly reduces myocardial infarct size; this effect is associated with cyclooxygenase-2 (COX-2) upregulation and is ablated by COX-2 inhibitors. However, pharmacological inhibitors are limited by relative lack of specificity; furthermore, the mechanism whereby iNOS gene therapy upregulates COX-2 remains unknown. Accordingly, we used genetically engineered mice to test the hypothesis that the cardioprotection afforded by iNOS gene transfer is mediated by COX-2 upregulation via a nuclear factor (NF)-kappaB-dependent pathway. METHODS AND RESULTS:Mice received an intramyocardial injection of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 3 days later, myocardial infarction was produced by a 30-minute coronary occlusion followed by 4 hours of reperfusion. Among Av3/LacZ-treated mice, infarct size was similar in COX-2(-/-) and wild-type groups. iNOS gene transfer (confirmed by iNOS immunoblotting and activity assays) markedly reduced infarct size in wild-type mice but failed to do so in COX-2(-/-) mice. In transgenic mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha(S32A,S36A)), the upregulation of phosphorylated IkappaB alpha, activation of NF-kappaB, and cardiac COX-2 protein expression 3 days after iNOS gene therapy were abrogated, which was associated with the abolishment of the cardioprotective effects afforded by iNOS gene therapy. CONCLUSIONS: These data provide strong genetic evidence that COX-2 is an obligatory downstream effector of iNOS-dependent cardioprotection and that NF-kappaB is a critical link between iNOS and COX-2. Thus, iNOS imparts its protective effects, at least in part, by recruiting NF-kappaB, leading to COX-2 upregulation. However, COX-2 does not play an important cardioprotective role under basal conditions (when iNOS is not upregulated).
Authors: Y Guo; W K Jones; Y T Xuan; X L Tang; W Bao; W J Wu; H Han; V E Laubach; P Ping; Z Yang; Y Qiu; R Bolli Journal: Proc Natl Acad Sci U S A Date: 1999-09-28 Impact factor: 11.205
Authors: Patrick Y Jay; Olga Rozhitskaya; Oleg Tarnavski; Megan C Sherwood; Adam L Dorfman; Yali Lu; Tomomi Ueyama; Seigo Izumo Journal: FASEB J Date: 2005-06-22 Impact factor: 5.191
Authors: S G Morham; R Langenbach; C D Loftin; H F Tiano; N Vouloumanos; J C Jennette; J F Mahler; K D Kluckman; A Ledford; C A Lee; O Smithies Journal: Cell Date: 1995-11-03 Impact factor: 41.582
Authors: Zhaokang Cheng; Laura A DiMichele; Zeenat S Hakim; Mauricio Rojas; Christopher P Mack; Joan M Taylor Journal: Arterioscler Thromb Vasc Biol Date: 2012-03-01 Impact factor: 8.311
Authors: Steven P Jones; Xian-Liang Tang; Yiru Guo; Charles Steenbergen; David J Lefer; Rakesh C Kukreja; Maiying Kong; Qianhong Li; Shashi Bhushan; Xiaoping Zhu; Junjie Du; Yibing Nong; Heather L Stowers; Kazuhisa Kondo; Gregory N Hunt; Traci T Goodchild; Adam Orr; Carlos C Chang; Ramzi Ockaili; Fadi N Salloum; Roberto Bolli Journal: Circ Res Date: 2014-12-11 Impact factor: 17.367
Authors: Muhammad R Afzal; Husnain Kh Haider; Niagara Muhammad Idris; Shujia Jiang; Rafeeq P H Ahmed; Muhammad Ashraf Journal: Antioxid Redox Signal Date: 2010-03-15 Impact factor: 8.401
Authors: Monica G Ferrini; Istvan Kovanecz; Sandra Sanchez; Chiome Umeh; Jacob Rajfer; Nestor F Gonzalez-Cadavid Journal: J Sex Med Date: 2008-12-02 Impact factor: 3.802